PIM
NRIX icon

Ponoi II Management’s Nurix Therapeutics NRIX Stock Holding History

Ponoi II Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$4.26M Hold
327,123
– – 11.14% 3
2022
Q2 		$4.14M Hold
327,123
– – 11.26% 3
2022
Q1 		$4.58M Hold
327,123
– – 10.17% 3
2021
Q4 		$9.47M Sell
327,123
-234,451
-42% -$7.11M 17.2% 3
2021
Q3 		$16.8M Sell
561,574
-124,700
-18% -$3.85M 24.93% 3
2021
Q2 		$18.2M Hold
686,274
– – 14.76% 4
2021
Q1 		$21.3M Hold
686,274
– – 16.34% 4
2020
Q4 		$22.6M Buy
+686,274
New +$22.7M 16.44% 4

Other funds holding NRIX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ponoi II Management's NRIX Position: Q3 2022 in Review

Ponoi II Management held its Nurix Therapeutics (NRIX) position steady in Q3 2022 at 327,123 shares worth $4.26M. The position accounts for 11.14% of the portfolio, ranked #3.

Ponoi II Management first reported a position in NRIX in Q4 2020 and has held it in 8 quarters since. The position peaked at $22.6M in Q4 2020. 118 funds tracked by Wall St. Rank hold NRIX as of Q3 2022.

  • Ponoi II Management held 327,123 shares of Nurix Therapeutics worth $4.26M as of Q3 2022.
  • Ponoi II Management left its Nurix Therapeutics share count unchanged in Q3 2022.
  • Nurix Therapeutics made up 11.14% of Ponoi II Management's portfolio in Q3 2022, its #3 holding.
  • Ponoi II Management first reported a position in Nurix Therapeutics in Q4 2020 and has held it in 8 quarters since.
  • Ponoi II Management's Nurix Therapeutics position peaked at $22.6M in Q4 2020.
  • 118 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2022.

Based on Ponoi II Management's 13F filing for Q3 2022, filed 14 Nov 2022.